Sutro Biopharma: Difference between revisions
CSV import |
CSV import |
||
| Line 46: | Line 46: | ||
[[Category:Companies established in 2003]] | [[Category:Companies established in 2003]] | ||
[[Category:Biopharmaceutical companies]] | [[Category:Biopharmaceutical companies]] | ||
<gallery> | |||
File:111_Oyster_Point_Blvd.jpg|111 Oyster Point Blvd | |||
</gallery> | |||
Latest revision as of 20:57, 25 February 2025
Sutro Biopharma is a biotechnology company based in South San Francisco, California. The company specializes in the development of therapeutics for the treatment of cancer and other serious diseases. Sutro Biopharma utilizes a proprietary cell-free protein synthesis technology to develop its products.
History[edit]
Sutro Biopharma was founded in 2003. The company has focused on developing a platform for the rapid and efficient production of complex biologics, including antibody-drug conjugates (ADCs) and bispecific antibodies.
Technology[edit]
Sutro's cell-free protein synthesis platform allows for the precise and rapid production of proteins. This technology is particularly useful in the development of ADCs, which are designed to deliver cytotoxic agents directly to cancer cells, minimizing damage to healthy cells.
Products and Pipeline[edit]
Sutro Biopharma is actively developing a pipeline of therapeutic candidates. The company's lead product candidates include:
- STRO-001: An ADC targeting CD74, being developed for the treatment of hematologic malignancies.
- STRO-002: An ADC targeting folate receptor alpha, being developed for the treatment of ovarian cancer and other solid tumors.
Collaborations[edit]
Sutro Biopharma has established collaborations with several major pharmaceutical companies to advance its technology and product candidates. These collaborations include partnerships with companies such as Merck & Co., Bristol-Myers Squibb, and EMD Serono.
See also[edit]
References[edit]
<references />
External links[edit]
-
111 Oyster Point Blvd
